{
  "trial_id": "NCT03588533",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Gastric or gastroesophageal junction adenocarcinoma",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "HER-2 immuno-histochemical (IHC) (3 +) stain or her-2 silver in situ hybridization(SISH)/fluorescence in situ hybridization(FISH) (+)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Herzuma\u00ae -capecitabine/cisplatin combination regimen is planned as a first line treatment",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Other type of cancer of Gastric or gastroesophageal junction adenocarcinoma (e.g., lymphoma, sarcoma)",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "HER-2 (0/1+) in IHC or her-2 SISH/FISH (-)",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patients who previously performed stomach cancer treatment as a palliative setting",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "12 year old girl with Turner syndrome, treating with GH since 6 months ago without estrogen therapy.",
  "_meta": {
    "topic_id": "49",
    "trial_id": "NCT03588533",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}